Grant: Engage Grants Program
University of Alberta
$24,000.00
Discovery of novel polyamine and metabolite biomarkers for early diagnosis of lung cancer and monitoring chemotherapy treatment response
FY 2014-15
Summary
BioMark Technologies (BioMark) is a Vancouver, BC-based company that develops innovative moleculardiagnostic technologies for early detection and management of different cancers. BioMark's technologies arebased on the polyamine metabolic pathway, which is involved in normal cell growth and proliferation in alleukaryotes. The polyamine pathway has also been demonstrated to be significantly up-regulated in cancer cells.In proof-of-concept experiments, BioMark has demonstrated that higher concentrations of metabolites in thepolyamine pathway are linked with early stage lung cancer. In this project we propose to extend this work bydeveloping a specialized metabolomic-based assay for measuring the polyamine pathway metabolites inhealthy and lung cancer populations to determine whether polyamines can serve as a diagnostic biomarker ofearly stage lung cancer. We will also use this specialized assay to determine whether the polyamine pathwaycan provide useful information as a marker of treatment response in lung cancer patients. Biomarkers for earlystage lung cancer will have significant impact on patient outcomes and health care costs.
Program
Engage Grants Program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
476924-2014
Name nom
Wishart, David
Department département
Computing Science
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
24000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Discovery of novel polyamine and metabolite biomarkers for early diagnosis of lung cancer and
monitoring chemotherapy treatment response
Keyword
NSERC
Application summary
BioMark Technologies (BioMark) is a Vancouver, BC-based company that develops innovative moleculardiagnostic technologies for early detection and management of different cancers. BioMark's technologies arebased on the polyamine metabolic pathway, which is involved in normal cell growth and proliferation in alleukaryotes. The polyamine pathway has also been demonstrated to be significantly up-regulated in cancer cells.In proof-of-concept experiments, BioMark has demonstrated that higher concentrations of metabolites in thepolyamine pathway are linked with early stage lung cancer. In this project we propose to extend this work bydeveloping a specialized metabolomic-based assay for measuring the polyamine pathway metabolites inhealthy and lung cancer populations to determine whether polyamines can serve as a diagnostic biomarker ofearly stage lung cancer. We will also use this specialized assay to determine whether the polyamine pathwaycan provide useful information as a marker of treatment response in lung cancer patients. Biomarkers for earlystage lung cancer will have significant impact on patient outcomes and health care costs.